BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans

ANAHEIM, CA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx®”) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders (SUD), today announced their partnership with Truusight Health, a healthcare solutions and care navigation and management company, to bring the Company’s Recovery Program to self-funded health plans.

The rest is here:
BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans

Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

MONMOUTH JUNCTION, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg?for use in retinal?indications, today announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE).

Read more:
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Tauriga Sciences Inc. Officially Approved to Operate as a U.S. Government Vendor

Continue reading here:
Tauriga Sciences Inc. Officially Approved to Operate as a U.S. Government Vendor

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Patient screening begins immediately at NYU Langone Health

Read more here:
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that initial Phase 1 data on MB-105, a PSCA-targeted CAR T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), will be presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat, which is being held October 20 – 23, 2020.

Go here to read the rest:
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat

GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth

Read this article:
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis (GPP), also known as the GALLOP trial. GPP is a chronic, life-threatening, rare inflammatory disease with no approved therapies.

See the original post:
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine

See the article here:
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

Indus Holdings, Inc. Pre-Announces Record Q3 2020 Revenues in Excess of $14 Million, ~15% EBITDA Margins, and Positive Operating Income

SALINAS, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announced preliminary unaudited revenue and adjusted EBITDA for the third quarter ended September 30, 2020. All figures stated are in US Dollars. Based on a preliminary review, the Company currently anticipates:

The rest is here:
Indus Holdings, Inc. Pre-Announces Record Q3 2020 Revenues in Excess of $14 Million, ~15% EBITDA Margins, and Positive Operating Income

Susan Hirsch Joins Agenus’ Board of Directors

Link:
Susan Hirsch Joins Agenus’ Board of Directors